{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:06:20Z","timestamp":1790539580419,"version":"4.1.0"},"reference-count":18,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"unspecified","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["SLS-590571"],"award-info":[{"award-number":["SLS-590571"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2021,8,2]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Immune dysregulation in SLE and the corresponding immune-modulating and immunosuppressive nature of the treatments may play key roles in infection risk. We compared serious infection rates among individuals with incident SLE with the general population, and examined the role of treatment initiation in SLE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Newly diagnosed patients with SLE (2006\u20132013) and general population comparators from the Swedish Lupus Linkage cohort were followed for serious infection through 2016. Adjusted Cox and frailty models estimated the relative risk of first and recurrent infections, respectively. Using a new-user design, rates of serious infections were compared between disease-modifying antirheumatic drugs (DMARDs) and hydroxychloroquine (HCQ) initiators. We then evaluated three DMARDs (azathioprine, mycophenolate mofetil and methotrexate) in multivariable-adjusted models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Individuals with SLE experienced more infections (22% vs 6%), especially during the first year of follow-up, and recurrent serious infections were also more common (HR=2.22, 95%\u2009CI 1.93 to 2.56). DMARDs were associated with a higher rate of serious infection versus HCQ (HR=1.82, 95%\u2009CI 1.27 to 2.60), which attenuated after multivariable-adjustment (HR=1.30, 95%\u2009CI 0.86 to 1.95). Among DMARDs, azathioprine was associated with infection (HR=2.19, 95%\u2009CI 1.14 to 4.21) and mycophenolate mofetil yielded an HR=1.39 (95% CI 0.65 to 2.96) in multivariable-adjusted models compared with methotrexate. Results were comparable across numerous sensitivity analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Individuals with incident SLE were 2\u20134 times more likely to be hospitalised for infection and experienced more recurrent infections than the general population. Among DMARD initiators, azathioprine was associated with the highest rate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2021-000510","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T13:04:08Z","timestamp":1631711048000},"page":"e000510","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Infection hospitalisation in systemic lupus in Sweden"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5735-9856","authenticated-orcid":false,"given":"Julia F","family":"Simard","sequence":"first","affiliation":[{"name":"Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, California, USA"},{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-324X","authenticated-orcid":false,"given":"Marios","family":"Rossides","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Gunnarsson","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3396-3244","authenticated-orcid":false,"given":"Elisabet","family":"Svenungsson","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth V","family":"Arkema","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"2025091512565823000_8.1.e000510.1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3904\/kjim.2016.234","article-title":"Infection in systemic lupus erythematosus, similarities, and differences with lupus flare","volume":"32","author":"Jung","year":"2017","journal-title":"Korean J Intern Med"},{"key":"2025091512565823000_8.1.e000510.2","doi-asserted-by":"crossref","unstructured":"Chen P-M , Tsokos GC . T cell abnormalities in the pathogenesis of systemic lupus erythematosus: an update. Curr Rheumatol Rep 2021;23.doi:10.1007\/s11926-020-00978-5","DOI":"10.1007\/s11926-020-00978-5"},{"key":"2025091512565823000_8.1.e000510.3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/art.39849","article-title":"Comparative rates of serious infections among patients with systemic lupus erythematosus receiving immunosuppressive medications","volume":"69","author":"Feldman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025091512565823000_8.1.e000510.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150671"},{"key":"2025091512565823000_8.1.e000510.5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10067-018-4259-z","article-title":"Causes of death in hospitalized patients with systemic lupus erythematosus: a 10-year multicenter nationwide Chinese cohort","volume":"38","author":"Wu","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025091512565823000_8.1.e000510.6","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1177\/0961203318811598","article-title":"Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort","volume":"27","author":"Gonz\u00e1lez-Echavarri","year":"2018","journal-title":"Lupus"},{"key":"2025091512565823000_8.1.e000510.7","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1089\/jwh.2017.6334","article-title":"Impact of sex on systemic lupus erythematosus-related causes of premature mortality in the United States","volume":"26","author":"Falasinnu","year":"2017","journal-title":"J Womens Health"},{"key":"2025091512565823000_8.1.e000510.8","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab219","article-title":"Increased risk of severe infections and mortality in patients with newly diagnosed systemic lupus erythematosus: a population-based study","author":"Zhao","year":"2021","journal-title":"Rheumatology"},{"key":"2025091512565823000_8.1.e000510.9","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313493032"},{"key":"2025091512565823000_8.1.e000510.10","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1177\/0961203318792352","article-title":"Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort","volume":"27","author":"Yang","year":"2018","journal-title":"Lupus"},{"key":"2025091512565823000_8.1.e000510.11","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/art.39070","article-title":"Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis","volume":"67","author":"Feldman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025091512565823000_8.1.e000510.12","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.semarthrit.2020.06.004","article-title":"Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis of observational studies","volume":"50","author":"Yuan","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025091512565823000_8.1.e000510.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008259"},{"key":"2025091512565823000_8.1.e000510.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-009-9350-y"},{"key":"2025091512565823000_8.1.e000510.15","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/acr.21959","article-title":"Systematic review of validation studies of the use of administrative data to identify serious infections","volume":"65","author":"Barber","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2025091512565823000_8.1.e000510.16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semarthrit.2017.01.010","article-title":"Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus","volume":"47","author":"R\u00faa-Figueroa","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025091512565823000_8.1.e000510.17","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008101028"},{"key":"2025091512565823000_8.1.e000510.18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00393-017-0410-5","article-title":"Insufficient vaccination rates in patients with systemic lupus erythematosus in a\u00a0German outpatient clinic","volume":"77","author":"Krasselt","year":"2018","journal-title":"Z Rheumatol"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2021-000510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T19:57:06Z","timestamp":1757966226000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2021-000510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,9,15]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/lupus-2021-000510"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2021-000510","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}